Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr‐/‐.Leiden Mice

Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr‐/‐.Leiden Mice

Concerns have been raised about whether preclinical models sufficiently mimic molecular disease processes observed in nonalcoholic steatohepatitis (NASH) patients, bringing into question their translational value in studies of therapeutic interventions in the process of NASH/fibrosis. We investigate...

Full description

Bibliographic Details
Main Authors:	Martine C. Morrison, Lars Verschuren, Kanita Salic, Joanne Verheij, Aswin Menke, Peter Y. Wielinga, Marta Iruarrizaga‐Lejarreta, Laurent Gole, Wei‐Miao Yu, Scott Turner, Martien P.M. Caspers, Ibon Martínez‐Arranz, Elsbet Pieterman, Reinout Stoop, Arianne van Koppen, Anita M. van den Hoek, José M. Mato, Roeland Hanemaaijer, Cristina Alonso, Robert Kleemann
Format:	Article
Language:	English
Published:	Wolters Kluwer Health/LWW 2018-12-01
Series:	Hepatology Communications
Online Access:	https://doi.org/10.1002/hep4.1270

Similar Items

Key Inflammatory Processes in Human NASH Are Reflected in Ldlr−/−.Leiden Mice: A Translational Gene Profiling Study
by: Martine C. Morrison, et al.
Published: (2018-02-01)

A casein hydrolysate based formulation attenuates obesity and associated non-alcoholic fatty liver disease and atherosclerosis in LDLr-/-.Leiden mice.
by: Marieke H Schoemaker, et al.
Published: (2017-01-01)

Unraveling the Transcriptional Dynamics of NASH Pathogenesis Affecting Atherosclerosis
by: Anita M. van den Hoek, et al.
Published: (2022-07-01)

Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice.
by: Kanita Salic, et al.
Published: (2019-01-01)

The Human Milk Oligosaccharide 2′-Fucosyllactose Alleviates Liver Steatosis, ER Stress and Insulin Resistance by Reducing Hepatic Diacylglycerols and Improved Gut Permeability in Obese Ldlr-/-.Leiden Mice
by: Eveline Gart, et al.
Published: (2022-06-01)

Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: a possible role for adiponectin and miR-21?
by: Martine C. Morrison, et al.
Published: (2017-06-01)

Butyrate Protects against Diet-Induced NASH and Liver Fibrosis and Suppresses Specific Non-Canonical TGF-β Signaling Pathways in Human Hepatic Stellate Cells
by: Eveline Gart, et al.
Published: (2021-12-01)

Translational characterization of the temporal dynamics of metabolic dysfunctions in liver, adipose tissue and the gut during diet-induced NASH development in Ldlr−/−.Leiden mice
by: Eveline Gart, et al.
Published: (2023-03-01)

Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice
by: Anita M. van denHoek, et al.
Published: (2020-02-01)

A Translational Mouse Model for NASH with Advanced Fibrosis and Atherosclerosis Expressing Key Pathways of Human Pathology
by: Anita M. van den Hoek, et al.
Published: (2020-09-01)

Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model
by: Arianne van Koppen, et al.
Published: (2018-01-01)

Cholesterol Accumulation as a Driver of Hepatic Inflammation Under Translational Dietary Conditions Can Be Attenuated by a Multicomponent Medicine
by: Andrea M. Mueller, et al.
Published: (2021-03-01)

Differential effects of drug interventions and dietary lifestyle in developing type 2 diabetes and complications: a systems biology analysis in LDLr-/- mice.
by: Marijana Radonjic, et al.
Published: (2013-01-01)

Semaglutide Has Beneficial Effects on Non-Alcoholic Steatohepatitis in Ldlr-/-.Leiden Mice
by: José A. Inia, et al.
Published: (2023-05-01)

Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid
by: Lianne R. de Haan, et al.
Published: (2021-02-01)

Obeticholic Acid for Primary Biliary Cholangitis
by: Annarosa Floreani, et al.
Published: (2022-10-01)

Ldlr-/-.Leiden mice develop neurodegeneration, age-dependent astrogliosis and obesity-induced changes in microglia immunophenotype which are partly reversed by complement component 5 neutralizing antibody
by: Florine Seidel, et al.
Published: (2023-06-01)

Obeticholic Acid—A Pharmacological and Clinical Review
by: Caezaan Keshvani, et al.
Published: (2023-02-01)

Content determination of obeticholic acid tablets by HPLC
by: Yunxia LU, et al.
Published: (2017-04-01)

Corrigendum: Ldlr-/-.Leiden mice develop neurodegeneration, age-dependent astrogliosis and obesity-induced changes in microglia immunophenotype which are partly reversed by complement component 5 neutralizing antibody
by: Florine Seidel, et al.
Published: (2023-08-01)

Krill Oil Treatment Increases Distinct PUFAs and Oxylipins in Adipose Tissue and Liver and Attenuates Obesity-Associated Inflammation via Direct and Indirect Mechanisms
by: Eveline Gart, et al.
Published: (2021-08-01)

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]
by: Brandon Ason, et al.
Published: (2014-11-01)

Obeticholic Acid and Insulin Sensitivity in Overweight Patients with Prediabetes
by: H. Amer, et al.
Published: (2021-12-01)

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
by: Marianne G. Pouwer, et al.
Published: (2018-06-01)

Current and Future Nutritional Strategies to Modulate Inflammatory Dynamics in Metabolic Disorders
by: Willem van den Brink, et al.
Published: (2019-08-01)

Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice
by: Szu-Yu Liu, et al.
Published: (2022-01-01)

Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice.
by: Szu-Yu Liu, et al.
Published: (2022-01-01)

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
by: Chuangzhen Lin, et al.
Published: (2022-05-01)

Atorvastatin Attenuates Diet-Induced Non-Alcoholic Steatohepatitis in APOE*3-Leiden Mice by Reducing Hepatic Inflammation
by: José A. Inia, et al.
Published: (2023-04-01)

The Surging Function of Nanotechnology in the Management of Primary Biliary Cholangitis with Obeticholic Acid
by: Devyani Patil, et al.
Published: (2023-05-01)

Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites
by: Kathleen Yan, et al.
Published: (2021-09-01)

Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
by: Surain B. Roberts, et al.
Published: (2020-09-01)

Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
by: Jiyu Zhou, et al.
Published: (2019-05-01)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
by: S Di Matteo, et al.
Published: (2019-01-01)

Therapeutic Intervention with Anti-Complement Component 5 Antibody Does Not Reduce NASH but Does Attenuate Atherosclerosis and MIF Concentrations in Ldlr-/-.Leiden Mice
by: Florine Seidel, et al.
Published: (2022-09-01)

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
by: Kowdley, K, et al.
Published: (2018)

Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis
by: Binu V. John, et al.
Published: (2021-08-01)

Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
by: Ludovico Abenavoli, et al.
Published: (2018-10-01)

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
by: Jhaveri MA, et al.
Published: (2017-08-01)

Mechanism-Based Biomarker Prediction for Low-Grade Inflammation in Liver and Adipose Tissue
by: Jolanda H. M. van Bilsen, et al.
Published: (2021-11-01)